Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Study sponsor: Geron Corporation
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2023-10-13Actual
Enrollment · participants289Actual
Source updated2026-07-17Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.